Study on Oral Compound γ-Aminobutyric Acid(GABA CO)Increase the Secretion of Growth Hormone in Children with Dwarfism
Objective To explore the oral compound γ-Aminobutyric acid(GABA CO)increases the secretion of growth hormone in children with dwarfism.Methods A total of 80 children with nanosomia treated in Fujian Longyan People's Hospital from April 2020 to March 2021 were randomly selected as study subjects and divided into study group and control group by random number table method,with 40 cases in each group.The children in the control group were given vitamin B12 related adjuvant therapy,and the children in the study group were given oral GABA CO therapy on the basis of adjuvant therapy,and the two groups were given continuous medication for 6 months.Follow up for 2 years,the height,body mass and bone age,serum insulin-like growth factor 1(IGF-1),insulin-like growth factor binding protein-3(IGFBP-3)levels,25-hydroxyvitamin D levels,the incidence of adverse reactions such as nerve fatigue,anorexia and blood pressure decrease during treatment of the two groups were compared before and after treatment.Results After 6 months,1 year and 2 years of follow-up,the height,body mass index and bone age of chil-dren in both groups were higher than before treatment,and the height of children in the study group and at different times points were(112.47±5.36)cm,(134.51±6.19)cm,(162.27±6.22)cm,which were higher than(106.51±5.62)cm,(121.36±6.52)cm,(150.54±6.31)cm in the control group;body mass index and bone age in the study group were higher than those in control group,the differences were statistically significant(all P<0.05).After 6 months,1 year and 2 years of follow-up,the levels of IGF-1 and 25 hydroxy-vitamin D in 2 groups were higher than before treat-ment,and the levels of IGF-1 and 25 hydroxy-vitamin D in the study group were higher than those in the control group,the differences were statistically significant(all P<0.05).After 1 year and 2 years of follow-up,the level of IGFBP-3 in the study group was higher than that in the control group,and the differences were statistically significant(both P<0.05).During treatment,there was no statistically significant difference in the incidence of adverse reactions between the study group(7.50%)and the control group(10.00%)(χ2=0.157,P>0.05).Conclusion Oral of GABA CO can promote the growth and development of children with dwarfism and increase their growth factor levels.
万方数据
维普
